Comprehensive analysis of β-catenin target genes in colorectal carcinoma cell lines with deregulated Wnt/β-catenin signaling

Andreas Herbst1*, Vindi Jurinovic2, Stefan Krebs3, Susanne E Thieme3, Helmut Blum3, Burkhard Göke1 and Frank T Kolligs1

Abstract

Background: Deregulation of Wnt/β-catenin signaling is a hallmark of the majority of sporadic forms of colorectal cancer and results in increased stability of the protein β-catenin. β-catenin is then shuttled into the nucleus where it activates the transcription of its target genes, including the proto-oncogenes MYC and CCND1 as well as the genes encoding the basic helix-loop-helix (bHLH) proteins ASCL2 and ITF-2B. To identify genes commonly regulated by β-catenin in colorectal cancer cell lines, we analyzed β-catenin target gene expression in two non-isogenic cell lines, DLD1 and SW480, using DNA microarrays and compared these genes to β-catenin target genes published in the PubMed database and DNA microarray data presented in the Gene Expression Omnibus (GEO) database.

Results: Treatment of DLD1 and SW480 cells with β-catenin siRNA resulted in differential expression of 1501 and 2389 genes, respectively. 335 of these genes were regulated in the same direction in both cell lines. Comparison of these data with published β-catenin target genes for the colon carcinoma cell line LS174T revealed 193 genes that are regulated similarly in all three cell lines. The overlapping gene set includes confirmed β-catenin target genes like AXIN2, MYC, and ASCL2. We also identified 11 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that are regulated similarly in DLD1 and SW480 cells and one pathway – the steroid biosynthesis pathway – was regulated in all three cell lines.

Conclusions: Based on the large number of potential β-catenin target genes found to be similarly regulated in DLD1, SW480 and LS174T cells as well as the large overlap with confirmed β-catenin target genes, we conclude that DLD1 and SW480 colon carcinoma cell lines are suitable model systems to study Wnt/β-catenin signaling and associated colorectal carcinogenesis. Furthermore, the confirmed and the newly identified potential β-catenin target genes are useful starting points for further studies.

Keywords: Colorectal cancer, β-catenin, Target genes, DLD1, SW480, LS174T, DNA microarray

Background

The majority of sporadic forms of colorectal cancer are characterized by deregulation of Wnt/β-catenin signaling resulting in increased transcriptional activity of the protein β-catenin. In colon cells, a protein complex consisting of the protein Adenomatous polyposis coli (APC), the scaffolding protein Axin, casein kinase 1 (CK-1) and glycogen synthase kinase 3β (GSK-3β) tightly controls the transcriptional activity of the β-catenin protein by targeting it for proteasomal degradation. Stimulation of colon cells with Wnt proteins results in the disruption of the APC protein complex and stabilization of the β-catenin protein. β-catenin is then transported into the nucleus where it recruits cofactors of the TCF/LEF family to activate the transcription of its target genes [1]. In colorectal tumor cells, the tumor suppressor gene APC is frequently affected by loss of heterozygosity (LOH) as well as mutations, resulting in inactivation of the APC protein complex targeting β-catenin for degradation [2,3]. Consequently, β-catenin activity is deregulated and promotes aberrant transcription of its target genes [1].

* Correspondence: Andreas.Herbst@med.uni-muenchen.de
1Department of Medicine II, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
Full list of author information is available at the end of the article

© 2014 Herbst et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
β-catenin target genes have been implicated in regulating different cellular processes including proliferation (e.g., MYC, CCND1, PPARD), stem cell fate (ASCL2), survival (ABCB1, BIRC5), differentiation (ID2, ITF2, ENC1), migration (MMP7, MMP14), and angiogenesis (VEGF) [4-18]. While these β-catenin functions play an important role in embryonic development and tissue homeostasis, they can also contribute to the initiation and progression of colon cancer. In particular, deregulation of genes involved in proliferation and migration is frequently observed in colorectal carcinomas [5-7,14-16].

Genes encoding members of the basic helix-loop-helix (bHLH) family of proteins, like ASCL2, HATH1, and ITF2, represent one of the largest groups of genes on the list of previously published β-catenin target genes [8,19,20]. Members of the bHLH protein family are characterized by the presence of a basic DNA binding domain and a HLH protein-protein interaction domain. Based on their primary sequence, bHLH proteins are grouped into seven classes and are known to form homo- and heterodimers to regulate their functions [21]. For example, the class I bHLH protein ITF-2B encoded by the gene ITF2 is known to interact with class II and class V bHLH proteins [22].

The colon carcinoma cell lines, DLD1 and SW480, are frequently used as model systems to study colorectal carcinogenesis in general and β-catenin function in particular. To identify target genes that are commonly regulated by β-catenin, we chose these non-isogenic colorectal cancer cell lines for our experiments. While DLD1 cells are derived from a microsatellite instable (MSI) tumor, SW480 tumor cells are characterized by chromosomal instability (CIN) [23]. In both cell lines the APC gene is affected by LOH on chromosome 5 and contains inactivating mutations in the remaining APC allele [24]. In contrast, the MSI colon carcinoma cell line LS174T – that was used for validation purposes – expresses wild-type APC and a mutated β-catenin protein [23,24].

Here, we analyzed the gene expression profiles of DLD1 and SW480 cells after down regulation of β-catenin expression and compared the potential β-catenin target genes that are similarly regulated in DLD1 and SW480 cells with a comparable data set published for LS174T cells in the Gene Expression Omnibus (GEO) database as well as confirmed β-catenin target genes found in the PubMed database. We also identified 11 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways that are regulated similarly in DLD1 and SW480 cells. In addition, one KEGG pathway was regulated in all three cell lines. Based on the large number of genes that are regulated in a similar way in DLD1, SW480, and LS174T cells as well as the large overlap with previously published β-catenin target genes, we conclude that DLD1 and SW480 are good model systems to study β-catenin target genes and signaling pathways. Furthermore, we were able to confirm a large number of previously published β-catenin target genes and identified many new potential β-catenin target genes. Therefore, this data is a useful resource for further studies to elucidate the role of β-catenin signaling in colorectal cancer.

**Results**

**Identification of β-catenin target genes in DLD1 and SW480 colon carcinoma cells**

To test the efficacy of the β-catenin siRNA used for our DNA microarray experiments, DLD1 and SW480 cells were treated with this β-catenin siRNA and β-catenin protein expression was analyzed using immuno detection. Since we observed the strongest down regulation of β-catenin protein after siRNA treatment for 48 hrs, cells were treated for this period of time. Compared to DLD1 and SW480 cells treated with control siRNA (siβgal), treatment with β-catenin siRNA (siβcat) attenuated β-catenin protein expression levels in both cell lines (Figure 1A). Similarly, treatment of DLD1 and SW480 cells with β-catenin siRNA strongly reduced the activity of the β-catenin dependent

![Image of graph showing validation of β-catenin siRNA](http://www.biomedcentral.com/1471-2164/15/74)
FGF18, HEF1 (NEDD9), and ITF2 (TCF4) were also differentially regulated in DLD1 and SW480 cells (see Additional file 2, “DLD1_SW480_LS174T_only” and tab “DLD1_SW480_complete”). Thus, our second analysis using a limited number of genes confirmed our first microarray analysis using all differentially expressed genes and identified the genes ITF2 (TCF4), NOTCH2 and SP5 as β-catenin target genes in addition to ABCB1, ASCL2, AXIN2, CD44, FGF18, MYC, HEF1 (NEDD9), and S100A6 found in the first analysis.

Due to the large number of genes encoding members of the basic helix-loop-helix (bHLH) family of proteins among the list of β-catenin target genes (6 out 66 genes; Table 1), we were interested in identifying more members of this family of genes in our microarray data set.

When we re-analyzed the microarray data limiting our analysis to the 96 bHLH proteins listed in the PFAM database, we identified the genes ASCL2 and MYC as differentially regulated in DLD1, SW480, and LS174T cells (see Additional file 3, tab “DLD1_SW480_LS174T_only”). In DLD1 and SW480 cells, the genes ID1, and ITF2 (TCF4) were also differentially regulated (Figure 2C and Additional file 3, tab “DLD1_SW480_complete”). Taken together, out of the six β-catenin target genes belonging to the bHLH family of proteins (Table 1), three genes (ASCL2, ITF2 (TCF4), MYC) are commonly regulated in DLD1 and SW480 cells.

Using the software package “Cytoscape” in combination with the “Michigan Molecular Interactions” (MiMI) plugin, we searched the list of 193 genes that are differentially regulated in DLD1, SW480, and LS174T cells for known interactions. We identified three networks that contained three or more nodes (genes) (Figure 3A). The largest network centered on β-catenin comprised 18 genes, while the second largest network with 6 genes contained the gene YWHAZ encoding the 14-3-3 protein isoforms ε/δ at its center. The smallest network contained the three nodes NET1, ARHGAP29, and DEPDC7 (Figure 3A). When we focused our analysis on the list of 335 genes that are differentially regulated in DLD1 and SW480 cells, we identified the same three networks that we found in the intersection of DLD1, SW480, and LS174T cells. However, the network centered on β-catenin was increased to 36 genes, while the network containing the gene YWHAZ comprised two additional nodes (8 in total). The smallest network contained the four nodes NET1, ARHGAP29, ABR and DEPDC7 (Figure 3B). Interestingly, both panels highlight the β-catenin target gene MYC as a major player with 10 and 19 directly regulated genes, respectively (Figure 3A and B).

Apart from identifying potential β-catenin target genes, we were interested to find out if particular signaling pathways or cellular functions are regulated by β-catenin. We used the gene set enrichment software (GSEA) software [80,81] to identify pathways associated with β-catenin.

To identify commonly regulated β-catenin target genes in colorectal cancer cell lines, we analyzed the expression of β-catenin target genes in DLD1 and SW480 cells after siRNA treatment of these cells using DNA microarrays. Treatment of DLD1 and SW480 cells with siRNA targeting β-catenin resulted in differential expression of 1501 and 2389 genes, respectively (Figure 2A and Additional file 1, tab “DLD1 complete” and “SW480 complete”). The intersecting set comprised 335 genes, which are regulated in the same direction in both cell lines (Figure 2A and Additional file 1, tab “335 target genes”). We compared the lists of potential β-catenin target genes obtained for DLD1 and SW480 cells to a previously published data set containing differentially expressed genes after treatment of the colon carcinoma cell line LS174T with β-catenin shRNA. Out of the 5543 differentially expressed genes in LS174T cells (Additional file 1, tab “LS174T_complete”), 786 genes and 677 genes were regulated similarly in DLD1 and SW480 cells, respectively. Furthermore, we identified 193 genes that are regulated in the same direction in all three cell lines (Figure 2A and Additional file 1, tab “DLD1_SW480_LS174T_only”).

Out of the 193 genes that are up or down regulated in DLD1, SW480, and LS174T cells, 4 genes (ASCL2, AXIN2, MYC, and S100A6) have previously been described as β-catenin target genes (compare Table 1 and Additional file 1, tab “DLD1_SW480_LS174T_only”; This tab also contains the false discovery rate (FDR) as well as the fold change (FC) for each gene). In addition, we identified the genes ABCB1, CD44, FGF18, and HEF1 (NEDD9) as potential β-catenin target genes in DLD1 and SW480 cells (Additional file 1, tab “LS174T_complete”); 786 genes and 677 genes were regulated similarly in DLD1 and SW480 cells, respectively. Furthermore, we identified 193 genes that are regulated in the same direction in all three cell lines (Figure 2A and Additional file 1, tab “DLD1_SW480_LS174T_only”).

Based on a literature search in the PubMed database, we identified 33 genes that are regulated in a β-catenin dependent manner in addition to the 33 β-catenin target genes published by Roel Nusse. (All these genes are differentially regulated either in normal colon, colon carcinoma cells, or colon carcinoma cell lines.) 38 out of these 66 genes are directly regulated by β-catenin as demonstrated by ChIP, EMSA, or RGA with mutated (canonical) TCF4 binding sites (Table 1). When we reanalyzed the microarray data focusing our analysis only on the list of these 66 previously published β-catenin target genes, we identified 21 (DLD1), 30 (SW480), and 34 (LS174T) of these genes as differentially regulated in DLD1, SW480, and LS174T cells (see Additional file 2, “DLD1_SW480_LS174T_only” and tab “DLD1_SW480_complete”). Thus, our second analysis using a limited number of genes confirmed our first microarray analysis using all differentially expressed genes and identified the genes ITF2 (TCF4), NOTCH2 and SP5 as β-catenin target genes in addition to ABCB1, ASCL2, AXIN2, CD44, FGF18, MYC, HEF1 (NEDD9), and S100A6 found in the first analysis.

The β-catenin target genes, we were interested to find out if particular signaling pathways or cellular functions are regulated by β-catenin. We used the gene set enrichment software (GSEA) software [80,81] to identify pathways associated with β-catenin.

8xTOPflash reporter gene construct, confirming the efficacy of the β-catenin siRNA (Figure 1B).
siRNA treatment. In DLD1 and SW480 cells treated with control siRNA 2 KEGG pathways were enriched. These pathways comprised the glycine, serine and threonine metabolism as well as the renin angiotensin system. After down regulation of β-catenin expression levels, the following 9 KEGG pathways were enriched in DLD1 and SW480 cells: endocytosis, insulin signaling pathway, lysosome FC gamma r mediated phagocytosis, apoptosis, regulation of actin cytoskeleton, adipocytokine signaling, glycerolipid metabolism, lysosome and aldosterone regulated sodium reabsorption (Table 2). In addition, the steroid hormone biosynthesis pathway was enriched in DLD1, SW480, and LS174T cells after treatment with β-catenin siRNA (Table 2). Apart from the KEGG pathway database, we also used the Biocarta pathway database in the gene set enrichment analysis. Down regulation of β-catenin resulted in the enrichment of the M-calpain pathway, the Creb pathway, and the IGF1R pathway in DLD1 and SW480 cells (Additional files 4 and 5).

Discussion

β-catenin plays a crucial role in embryogenesis, tissue homeostasis and carcinogenesis. Because of its role in regulating homeostasis of the intestinal tract as well as being a key player in sporadic forms of colorectal cancer, inhibition of β-catenin is not a suitable strategy to treat patients with colorectal cancer. For this reason, identifying and characterizing β-catenin target genes could result in better understanding of colorectal carcinogenesis and development of new therapies. Here, we used two non-isogenic colorectal cancer cell lines, DLD1, and SW480, and identified 335 commonly regulated β-catenin target genes. 193 of these genes were also differentially regulated in LS174T cells. (Genes that are differentially expressed due to the genetic background of a given cell should be deregulated to a similar extent irrespective of the siRNA treatment and hence should not appear as being differentially regulated in the DNA microarray experiment.) Compared to the number of differentially regulated genes in LS174T and DLD1 cells (786 genes) as well as in LS174T and SW480 cells (677 genes), the number of commonly regulated genes in DLD1 and SW480 (335 genes) was low, resulting in a low number of commonly regulated genes in...
| Gene      | Protein                                                                 | Direct regulation | Method to study direct regulation                                                                 | Induction/Reduction | Reference |
|-----------|-------------------------------------------------------------------------|-------------------|---------------------------------------------------------------------------------------------------|---------------------|-----------|
| ABCB1     | ABC multidrug transporter                                                | Yes               | EMSA, RGA w/ mutated reporter gene                                                                | Up                  | [9]       |
| ADAM10    | Disintegrin and metalloproteinase domain-containing protein 1a           | Not analyzed      | RGA                                                                                                | Up                  | [25]      |
| ALEX1     | Armadillo repeat-containing X-linked protein 1                          | Not analyzed      | RGA, ChIP for CREB; activation mediated by CREB (CRE) und E boxes within the ALEX1 promoter      | Up                  | [26]      |
| ASCL2     | Achaete-scute homolog 2                                                 | Not analyzed      | qRT-PCR                                                                                            | Up                  | [8]       |
| AXIN2*    | Axin-2                                                                  | Not analyzed      | RGA                                                                                                | Up                  | [27-29]   |
| BAMBI     | BMP and activin membrane-bound inhibitor                                | Yes               | RGA w/ mutated reporter gene                                                                      |                     | [30]      |
| BCL2L2    | Bcl-2-like protein 2; BCLW                                             |                   |                                                                                                   |                     |           |
| BIRC5*    | Survivin, Baculoviral IAP repeat-containing protein 5                   |                   |                                                                                                   |                     |           |
| BMI1      | Polycomb complex protein BMI-1                                          | Not analyzed      | RGA                                                                                                | Up                  | [32]      |
| BMP4*     | Bone morphogenetic protein 4                                            | Not analyzed      | Northern blot                                                                                     | Up                  | [33]      |
| CCND1*    | Cyclin-D1                                                              |                   |                                                                                                   |                     |           |
| CD44*     | CD44 antigen                                                            | Not analyzed      |                                                                                                   | Up                  |           |
| CDKN2A    | p16INK4a                                                               | Yes               | ChIP                                                                                                | Up                  | [36]      |
| CDX1      | Homeobox protein Cdx-1                                                  | Yes               | RGA w/ mutated reporter gene                                                                      | Up                  | [37]      |
| CLDN1*    | Claudin-1                                                               | Yes               | RGA                                                                                                | Up                  | [38]      |
| COX2      | Cyclooxygenase-2                                                        | Yes               | EMSA, RGA w/ mutated reporter gene                                                                | Up                  | [39]      |
| DKK1*     | Dickkopf-1                                                             | Yes               | EMSA                                                                                                | Up                  | [40]      |
| DKK4*     | Dickkopf-4                                                             | Not analyzed      | RGA, siRNA/qRT-PCR                                                                                | Up                  | [41,42]   |
| DNMT1     | DNA methyltransferase 1                                                 | Not analyzed      | RGA                                                                                                | Up                  | [43]      |
| EDN1*     | endotheonin-1                                                           |                   |                                                                                                   |                     |           |
| EFNB1*    | Ephrin-B1                                                               | Not analyzed      | Northern blot                                                                                     | Down                | [45]      |
| ENC1      | ectodermal-neural cortex 1                                              | Yes               | RGA w/ mutated reporter gene                                                                      | Up                  | [13]      |
| EPHB2     | Ephrin type-B receptors                                                 | Not analyzed      | Northern blot                                                                                     | Up                  | [45]      |
| EPHB3     | Ephrin type-B receptors                                                 | Not analyzed      | Northern blot                                                                                     | Up                  | [45]      |
| FGF18*    | Fibroblast growth factor 18                                             | Yes               | EMSA                                                                                                | Up                  | [45,46]   |
| FGFBP     | Fibroblast growth factor-binding protein                                | Yes               | RGA w/ mutated reporter gene                                                                      | Up                  | [47]      |
| FRA1*     | Fos-related antigen 1                                                   | Yes               | EMSA                                                                                                | Up                  | [48]      |
| FSCN1     | Fascin1                                                                | Yes               | ChIP                                                                                                | Up                  | [49]      |
| GAST*     | Gastrin                                                                | Not analyzed      | RGA                                                                                                | Up                  | [50]      |
| HATH1*    | human ortholog of atonal1                                               | Not analyzed      | RGA                                                                                                | Down                | [19]      |
| HEF1 (NEDD9) | human enhancer of filamentation                                      |                   |                                                                                                   |                     |           |
| HES1      | Hes1 (Hairy and enhancer of split 1)                                    | Yes               | RGA w/ mutated reporter gene                                                                      | Up                  | [52]      |
| ID2*      | DNA-binding protein inhibitor ID-2                                       | Yes               | EMSA                                                                                                | Up                  | [11,12]   |
| IGF2 (TCF4)* | Immunoglobulin transcription factor 2                                   | Not analyzed      | RGA                                                                                                | Up                  | [20]      |
| JAG1*     | Jagged-1                                                                | Yes               | ChIP                                                                                                | Up                  | [53]      |
| JUN*      | Transcription factor AP-1                                               | Yes               | EMSA                                                                                                | Up                  | [48]      |
| L1CAM*    | L1 neuronal cell adhesion molecule                                       | Yes               | EMSA                                                                                                | Up                  | [54]      |
| LAMC2     | Laminin subunit gamma-2                                                 | Yes               | EMSA, RGA w/ mutated reporter gene                                                                | Up                  | [55]      |
Table 1 β-catenin target genes in human colon or colon carcinoma cells (including colon carcinoma cell lines) (Continued)

| Gene | Target | Protein | Regulation | Status | Reference |
|------|--------|---------|------------|--------|-----------|
| LEF1* | Lymphoid enhancer-binding factor 1 | Yes | DNAse footprint, ChIP | Up | [56-58] |
| LGR5* | Leucine-rich repeat-containing G-protein coupled receptor 5 | Not analyzed | – | Up | [59] |
| MENA | ENAH, Mammalian enabled homologue | Yes | ChIP | Up | [60] |
| MET* | Hepatocyte growth factor receptor | Not analyzed | – | Up | [61] |
| MMP14 | Matrix metalloproteinase-14 (old name: MT1-MMP) | Yes | EMSA, RGA w/ mutated reporter gene | Up | [16] |
| MMP7* | Matrilysin | Not analyzed | RGA | Up | [14,15] |
| MYB | Transcriptional activator Myb | Not analyzed | Northern blot | Up | [62] |
| MYC* | Myc proto-oncogene protein | Yes | EMSA | Up | [4] |
| MYCBP* | c-myc binding protein | Not analyzed | RGA | Up | [63] |
| NOS2* | Nitric Oxide Synthase 2 | Yes | EMSA | Up | [64] |
| NOTCH2 | NOTCH2 protein | Yes | EMSA, RGA w/ mutated reporter gene | Up | [65] |
| NRCAM* | Neuronal cell adhesion molecule | Not analyzed | RGA | Up | [66] |
| PLAU* | urokinase plasminogen activator | Yes | EMSA | Up | [67] |
| PLAUR | urokinase-type plasminogen activator receptor | Not analyzed | – | Up | [48] |
| PPARD* | PPARdelta | Yes | EMSA | Up | [7] |
| S100A4 | Protein S100-A4 | Yes | Chip, EMSA, RGA w/ mutated reporter gene | Up | [68] |
| S100A6 | Protein S100-A6 | Not analyzed | RGA | Up | [69] |
| SGK1 | Serum/glucocorticoid-regulated kinase 1 | Yes | ChIP | Up | [70] |
| SMC3 | Structural maintenance of chromosomes protein 3 | Yes | EMSA, RGA w/ mutated reporter gene | Up | [71] |
| SOX9* | Transcription factor Sox-9 | Not analyzed | Northern blot | Up | [72] |
| SP5 | Transcription factor Sp5 | Yes | EMSA | Up | [73] |
| SRSF3 (SRp20) | Serine/arginine-rich splicing factor 3 | Not | – | Up | [74] |
| SUZ12 | Polycomb protein SUZ12 | Yes | ChIP, EMSA | Up | [75] |
| TCF1* | Transcription factor 7 | Not analyzed | RGA | Up | [76] |
| TIAM1* | TIAM-1 | Not analyzed | Northern blot | Up | [77] |
| TN-C | Tenascin-C | Yes | ChIP | Up | [78] |
| VEGF* | Vascular endothelial growth factor | Not analyzed | RGA | Up | [17] |
| YAP | Yes-associated protein | Yes | ChIP | Up | [79] |

Based on a PubMed search, we identified 66 β-catenin target genes. Nusse et al. have previously reported 33 of these genes on their web site. (http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes; these genes are marked with an asterisk.). The gene and protein names follow the naming convention of the Swiss-Prot database (http://www.uniprot.org). A regulation of a given target gene by β-catenin had to be confirmed by chromatin immune precipitation (ChIP), electrophoretic mobility shift assay (EMSA), or reporter gene assays (RGA) with mutated TCF binding sites to be classified as “direct”.

DLD1, SW480, and LS174T cells (193 genes). While DLD1 and SW480 cells both express a mutated form of APC, they differ with respect to the underlying genetic disturbance: DLD1 cells show microsatellite instability (MSI), whereas SW480 cells are derived from a tumor with chromosomal instability (CIN). However, SW480 cells (CIN) share a lot of commonly regulated genes with LS174T cells (MSI), suggesting that other factors apart from genetic instability contribute to the observed differences in gene expression between DLD1 and SW480 cells. Looking at the mutational status, DLD1, SW480, and LS174T cells differ with respect to the status of the genes APC, PI3K, and TP53, but they are identical with respect to status of the genes KRAS and PTEN: DLD1 (APC: Mutant; TP53: WT; PI3K: Mutant; KRAS: Mutant; PTEN: WT), SW480 (APC: Mutant; TP53: Mutant; PI3K: WT; KRAS: Mutant; PTEN: WT), and LS174T cells (APC: WT; TP53: Mutant; PI3K: Mutant; KRAS: Mutant; PTEN: WT) [82,83].
Deregulation of PI3K/Akt signaling (as observed in DLD1 and LS174T) has been implicated in the phosphorylation of β-catenin at Ser552 [84], thereby promoting nuclear accumulation and enhancing β-catenin dependent transcriptional activity even in the absence of aberrant Wnt signaling [85,86]. This observation suggests that in particular LS174T cells that express wild-type APC could benefit from a mutation in the PI3K gene. But even DLD1 cells (with mutant APC) could profit from PI3K mutations: Deming et al. demonstrated that expression of a dominant active form of PI3K in ApcMin/+ mice resulted in an increased tumor number and size and implicated the CCND1 gene as one transcriptional target that contributes to the observed phenotype of these mice.

Figure 3 Identification of known interactions between differentially expressed β-catenin target genes in DLD1, SW480, and LS174T cells. Using the software package “Cytoscape” in combination with the “MiMI” plugin, we identified known interactions between the 193 differentially expressed β-catenin target genes in DLD1, SW480, and LS174T cells (A) and the 335 differentially expressed β-catenin target genes in DLD1 and SW480 cells (B). Only gene networks are displayed that contain three or more nodes. The genes highlighted in pink color have been previously described as β-catenin target genes (see Table 1).
In our experiments, CCND1 mRNA expression levels were upregulated in LS174T cells, but not in DLD1 cells. The tumor suppressor p53 has been implicated in down-regulating β-catenin expression and/or activity by Siah-1 dependent (and GSK-3β independent) degradation [88,89], reduction of TCF4 mRNA and protein levels [90] as well as reduction of β-catenin mRNA by p53 dependent regulation of miRNA miR-34 [91]. Accordingly, inactivation of the transcriptional activity of p53 by mutations –as observed in SW480 cells– should result in increased β-catenin mRNA and protein levels and transcriptional activity as well as increased mRNA and protein levels of TCF4 (TCF7L2). Interestingly, LS174T cells showed a strong increase in the fold change value for CTNNB1 (encoding β-catenin) (4.56 versus 1.59 (DLD1) and 1.18 (SW480), respectively). All three cell lines showed slightly reduced fold change values for TCF4 (TCF7L2). The effect of p53 inactivation on the development of intestinal adenomas was also analyzed in ApcMin/+ mice: Despite the fact that p53 protein expression is deregulated as a consequence of APC loss (and probably other factors) and p53 is known to regulate β-catenin expression via a negative feedback loop, loss of p53 did not promote the initial steps of intestinal neoplasia in ApcMin/+ mice [92], suggesting that p53 has only a limited role in this mouse model.

Table 2 Identification of signaling pathways enriched in more than one cell line

| Treatment | Intersection | Enriched KEGG pathways | Biocarta pathways |
|-----------|--------------|------------------------|------------------|
| β-catenin RNAi | DLD1/SW480 | Endocytosis, Insulin signaling pathway, Lysosome | mCalpain pathway |
| | | FC gamma R mediated phagocytosis, Apoptosis, Regulation of actin cytoskeleton, Glycerolipid metabolism, Focal adhesion | |
| | DLD1/LS174T | PPAR signaling pathway, Metabolism of xenobiotics by cytochrome P450, Butanoate metabolism | – |
| | SW480/LS174T | Complement and coagulation cascades, Histidine metabolism, Ether lipid metabolism, NOD like receptor signaling pathway | – |
| β-galactosidase RNAi | DLD1/SW480 | DNA replication, Base excision repair, Mismatch repair, Homologous recombination, Cell cycle, Nucleotide excision repair, Pyrimidine metabolism, RNA polymerase, RNA degradation | – |
| | DLD1/LS174T | DNA replication, Base excision repair, Mismatch repair, Homologous recombination, Cell cycle, Nucleotide excision repair, Pyrimidine metabolism, RNA polymerase, RNA degradation, Spliceosome | ATRBRCA pathway |
| | SW480/LS174T | Basal cell carcinoma | – |

Gene set enrichment analyses were performed after treatment of DLD1, SW480, and LS174T cells with β-catenin RNAi or β-galactosidase RNAi using the KEGG and the Biocarta pathway database, respectively. Pathways that were enriched in more than one cell line were identified using a Biovenn software package.
Apart from regulating β-catenin protein expression levels via proteasomal degradation, (nuclear) APC has been implicated in affecting β-catenin activity by recruiting corepressors of β-catenin to promoter regions, as well as sequestering and enhancing the nuclear export of β-catenin [93-96]. Mutated forms of APC still show a nuclear localization, but they are more frequently observed in the cytoplasm when compared to wild-type APC, suggesting that mutation of APC is not only contributing to higher β-catenin protein expression levels, but also contribute to enhanced β-catenin activity [97]. When Zeineldin et al. generated mice expressing APC with mutated nuclear localization signals (mNLS) and compared these Apc^mNLS/mNLS mice with Apc^+/+ mice, they found up regulation of the mRNA for the genes AXIN2, MYC, and CCND1 as well as down regulation of HATH1 mRNA in response to stimulation with Wnt [98]. Accordingly, we expected an increase in the fold change values for AXIN2, MYC, and CCND1 transcripts as well as a reduction of HATH1 transcripts in DLD1 and SW480 cells (APC mutated) compared to LS174T (APC wild-type). In our experiments, DLD1 and SW480 showed a modest increase in the fold change values for MYC (see Additional file 1, Table “DLD1_SW480_LS174T_only”) compared to LS174T cells. However, LS174T (and SW480) cells responded with a higher fold change for AXIN2 compared to DLD1 cells. CCND1 transcript levels were increased only in LS174T cells, whereas HATH1 transcript levels did not change in any of three cell lines.

The differential expression of the genes AXIN2 and CCND1 in the three colorectal cancer cell lines highlights the fact that the genetic background of a given cell has a major impact on the expression of a specific gene. However, linking a specific somatic mutation in a tumor suppressor gene or proto oncogene, e.g. APC, PI3K, or TP53, to these differences in expression is difficult because the expression of a specific gene is affected by multiple transcription factors (along with their cofactors and corepressors). Therefore, we are not able to attribute the observed differences in the gene expression profiles for DLD1 and SW480 to a single mutation.

Compared to LS174T cells, the total number of differentially regulated β-catenin target genes was much lower in DLD1 and SW480 cells. This could be either specific to the genetic background of the cell lines used or due to different experimental approaches. While we transiently transfected DLD1 and SW480 cells with β-catenin siRNA and analyzed the gene expression 48 hours after transfection, Mokry et al. [99] stably transfected LS174T cells with a doxycycline inducible expression vector encoding β-catenin shRNA and stimulated the cells for 72 hours with doxycycline before analyzing the gene expression profile. Both research groups used Affymetrix Human Genome U133 Plus 2.0 DNA microarrays for their experiments. The longer incubation period used to identify potential β-catenin target genes in LS174T cells might contribute to secondary effects like the differential expression of indirect β-catenin target genes, thus explaining why the absolute number of differentially regulated genes was higher in LS174T cells when compared to DLD1 and SW480 cells. For this reason, we were particularly interested in genes that are up and down regulated in the non-isogenic colorectal cancer cell lines DLD1 and SW480 or DLD1, SW480, and LS174T cells, assuming that these genes are commonly and directly regulated by β-catenin.

Remarkably, the number of β-catenin regulated genes was very similar in the three cell lines when focusing on the list of 66 previously described β-catenin target genes. Here, DLD1, SW480 and LS174T cells differentially regulated 21, 30 and 34 of these genes, respectively. There are at least two reasons why the number of detected β-catenin target genes did not include (almost) all 66 β-catenin target genes presented in Table 1. First, the detection of β-catenin target genes is dependent on the cellular context. DLD1, SW480, and LS174T represent colorectal cancer cell lines. Therefore, the expression pattern of β-catenin target genes in these cells is likely to differ from β-catenin target genes found in healthy colon cells, colonic adenomas, or metastatic colonic cells that are also listed in Table 1. Second, the gene expression profile was analyzed 48 and 72 hours after beginning with the RNAi treatment, respectively. Different periods of time influence the identification of β-catenin target genes as well, since some of these genes might be regulated only for a short period of time immediately after induction of β-catenin activity. This phenomenon has been described by Van de Wetering et al. (2002): They transfected LS174T cells with doxycycline (Dox) inducible expression vectors encoding dnTcFs and analyzed the changes in gene expression using DNA microarrays. 11 h after treatment with Dox, 2411 genes where differentially regulated. After an incubation period of 23 h, they identified 1199 differentially regulated genes. Comparison of the two sets of genes revealed that the expression of 1971 genes was abrogated between 11 and 23 h after Dox treatment, while 759 additional genes appeared in this time frame [62]. Similarly, another group analyzed the gene expression profiles of several known β-catenin target genes in a time-course experiment and classified these genes according to their expression profiles [100]. Based on this criterion, they identified genes that were “immediately up (or down) regulated”, “early up (down)”, or “late up (down)” in response to the activation of the Wnt/β-catenin signaling cascade. When comparing their results to the regulation of the same genes in different cellular contexts, this group found that the regulation of these genes was similar, but not necessarily identical in different cell lines. This observation suggests that the
expression levels and activities of a given transcription factor and its cofactors (or co-repressors) influence the starting point and duration of the gene expression of a specific target gene. Therefore, it is recommendable to identify target genes of a given transcription factor in different cell lines at least at the same time points, better yet in a time-course experiment.

Using the KEGG pathway database, we identified 11 signaling pathways or cellular functions in DLD1 and SW480 cells that are differentially regulated in response to treatment of the colorectal cancer cell lines with β-catenin siRNA. In addition, the steroid hormone biosynthesis pathway was similarly regulated in all three cell lines analyzed. Whereas the steroid hormone biosynthesis pathway [101,102] as well as the endocytosis pathway [103,104], the insulin signaling pathway [105,106], apoptosis [107,108], regulation of the actin cytoskeleton [49], and focal adhesion [109], have been associated with Wnt/β-catenin signaling, there are no publications in the PubMed database linking β-catenin to the remaining six pathways in colorectal cancer cells. Interestingly, the list of KEGG pathways/functions did not include the canonical Wnt signaling pathway. This was probably due to the definition of the "KEGG Wnt signaling pathway" that summarized the canonical, the planar cell polarity (PCP), and the Wnt/Ca²⁺ signaling pathway under one database entry, despite different functions of these signaling pathways. While the canonical Wnt pathway has been implicated in regulating the activity of the β-catenin protein, PCP signaling results in remodeling of the cytoskeleton that is a prerequisite for migration and cell polarization via the GTPases RHOA and RAC1. Wnt/Ca²⁺ signaling, however, plays a role in the regulation of cell adhesion and cell movements during gastrulation and results in the activation of protein kinase (PKC), calcium calmodulin mediated kinase II (CAMKII) and calcineurin [110].

Furthermore, all three Biocarta pathways that were enriched in DLD1 and SW480 cells have been associated with Wnt/β-catenin signaling based on PubMed publications: the m-calpain pathway [111,112], the Creb pathway [26,113], and the IGF1R pathway [114,115].

Since 6 out of the 66 previously described β-catenin target genes encode proteins that belong to the bHLH protein family (Table 1), we focused our analysis on this group of genes. Our analysis revealed that the genes ASCL2, ID1, ITF2, and MYC were regulated in a β-catenin dependent manner in DLD1 and SW480 cells. Interestingly, the proteins ASCL2 and ITF2-B as well as ID1 and ITF2-B are known to interact with each other [116,117], suggesting that these bHLH proteins form a functional network in colorectal carcinoma cells.

Conclusions
In conclusion, by comparing potential β-catenin target genes in DLD1 and SW480 cells with 1) corresponding data from LS174T cells and 2) a list of previously identified β-catenin target genes, we found and confirmed a large number of β-catenin target genes, suggesting that DLD1 and SW480 (as well as LS174T cells) are suitable for identifying β-catenin target genes as well as β-catenin dependent signaling pathways and functions. Therefore, the presented list of commonly regulated genes in DLD1 and SW480 cells as well as the annotated list of previously published β-catenin target genes are useful resources for further studies.

Methods
Cell culture
The colon carcinoma cell lines DLD1 and SW480 were obtained from ATCC (Manassas, VA, USA) and were cultured in DMEM medium supplemented with 10% calf serum (PAA, Pasching, Austria). Short interfering RNAs targeting β-catenin (cat. no. D-003482-04) and β-galactosidase (cat. no. D-012539-01) were purchased from Dharmacon (Lafayette, CO, USA) as siGenome siRNAs. Cells were transfected with these siRNAs using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA).

Immuno detection
Cell lysates were prepared with reporter gene lysis buffer (Promega, Mannheim, Germany) supplemented with protease inhibitor cocktail I (Calbiochem, Darmstadt, Germany). Equal amounts of protein were mixed with 2x SDS loading buffer (0.35 M Tris, pH 6.8; 30% (v/v) glycerol; 10% (w/v) SDS; 100 mM Dithiothreitol; 0.01% (w/v) bromophenol blue), separated by electrophoresis in discontinuous SDS-polyacrylamide gels and transferred to Immobilon-P membranes (Millipore, Billerica, MA, USA). Antibodies specific for β-catenin (BD Transduction Labs, San Jose, CA, USA), β-actin (MP Biomedicals, Eschwege, Germany) and the secondary horseradish peroxidase-conjugated goat anti-mouse antibody (GE Healthcare, Freiburg, Germany) were used for immuno detection. Blots were subjected to Supersignal West Dura chemiluminescence substrate (Thermo Scientific, Rockford, IL, USA) and exposed to Fuji Medical x-ray film SuperRX (FujiFilm).

Reporter gene assays
For reporter gene assays, 10⁵ DLD1 or SW480 cells were seeded per well (12 well plate). Cells were transfected with the indicated siRNAs using Lipofectamine 2000 (Life Technologies). 24 hours later, the 8×TOPflash reporter gene construct (a generous gift from Randall T. Moon, University of Washington) as well as the plasmid pCH110 encoding β-galactosidase (GE Healthcare, Freiburg, Germany) were transfected into these cells. 72 hours after the siRNA transfection, cells were harvested, lysed with reporter lysis buffer (Promega) and luciferase
activities were measured using a luciferase assay reagent (Promega) and a luminometer (Orion II, Berthold Detection Systems, Wildbad, Germany). β-galactosidase activity was determined by standard methods using o-Nitrophenyl β-D-galactopyranoside (ONPG, Sigma-Aldrich, Taufkirchen, Germany) as a control for transfection efficiency.

Microarray analysis
DLD1 and SW480 cells were harvested 48 h after siRNA transfection using TRIzol (Life Technologies, Darmstadt, Germany). Total RNA was isolated according to the manufacturer’s instructions and reverse transcribed using SuperScript II reverse transcriptase (Life Technologies) according to the instructions provided by the manufacturer. cDNA was amplified and labeled with biotin using kits from Affymetrix. Labeled probes were hybridized to Human Genome U133 Plus 2.0 microarrays (Affymetrix), washed, stained and scanned using equipment from Affymetrix. The microarray analysis was performed in triplicates for each cell line (see also the corresponding CEL files that are part of the accompanying GEO submission).

Identification of validated β-catenin target genes
We were particularly interested in β-catenin target genes that are regulated in normal colon or colon carcinoma cells or colon carcinoma cell lines. For this reason, the PubMed database was searched using the phrase “beta catenin AND target AND (colorectal OR colon OR intestinal OR intestine)”. 591 articles were identified (as of June 1st, 2012) and publications were screened for the identification and characterization of β-catenin target genes. We were able to identify 66 published β-catenin target genes that matched our criteria (Table 1). 33 out of the 66 genes have been published earlier by Nusse et al. on their web site http://www.stanford.edu/group/nusselab/cgi-bin/wnt/target_genes (last update: October 2010). These genes are marked with an asterisk after the gene name (Table 1).

Statistical analysis
For evaluation purposes, we compared genes differentially expressed in DLD1 and SW480 cells after treatment with β-catenin siRNA to a previously published data set containing differentially expressed genes after treatment of the colon carcinoma cell line LS174T with β-catenin shRNA (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18560). The software package R (version 2.14.1) was used for the statistical analysis of the microarray data. Microarray data were preprocessed using the rma function from the R package “affy”. The expression matrix was filtered to contain only those probe sets that can be assigned to a gene name. Log2 intensity values were used for all subsequent analyses. Differentially expressed genes were identified with the R package “limma”. Genes were called “differentially expressed” if the corrected p value (according to Benjamini-Hochberg) was lower than 0.05. We considered a gene to be significant only if all of its significant probe sets were regulated in the same direction. Genes with significant probe sets that were differently regulated were not considered significant because we could not determine if the gene is up- or down regulated.

Gene set enrichment analysis (GSEA)
The gene set enrichment analysis was performed using the GSEA software [80,81]. Due to the small sample size of our data sets, we used gene set permutation for the GSEA analysis. Probe sets belonging to the same gene were collapsed to a gene symbol and 1000 permutations were performed to find differentially expressed gene sets. If our data sets contained less than 15 genes of a certain gene set, the gene set was filtered out. After this restriction, 138 out of 217 Biocarta gene sets and 175 out of 186 KEGG gene sets were analyzed. Gene sets with a false discovery rate (FDR) lower than 0.25 were considered statistically significant. The corresponding files containing the data of the GSEA analysis are part of the Additional files. The names of the directories containing the files were composed of the term ‘GSEA’, the name of the cell line, e.g. DLD1, SW480, or LS174T, and the pathway database (KEGG or Biocarta). Please use the files with the name ‘index.html’ in the corresponding directories to start exploring the data.

KEGG and Biocarta pathways that are regulated similarly in two or three cell lines were identified using the Biovenn software (http://www.cmbi.ru.nl/cdd/biovenn/) [118].

Network visualization
Gene symbols of β-catenin target genes common to two or more cell lines were entered in the query function of the “Michigan molecular interaction” (MiMI) plugin (version 3.11) in the software package “Cytoscape” (version 2.83) [119,120]. Using the human database entries to analyze interactions between all molecule types and in all data sources, we searched for “Interactions among query genes”. Only networks that contained three or more nodes were displayed.

Availability of supporting data
The data sets supporting the results of this article are available NCBI’s Gene Expression Omnibus (GEO) repository [121]. The unique identifier for this dataset is GSE44097. The corresponding information can be found at the following web site: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE44097.
Additional files

**Additional file 1:** Table S1. Results of the DNA microarray analysis (all genes). DLD1, SW480, and LS174T cells were treated with siRNA or shRNA targeting beta-catenin. Differentially expressed genes were identified using DNA microarrays as described in Materials and Methods. Using the Biovenn software, genes that are regulated similarly in two or three cell lines were identified and listed under separate tabs. Accordingly, genes that are differentially expressed in only one cell line were listed in a separate tab labeled with the name of the cell line.

**Additional file 2:** Table S2. Results of the DNA microarray analysis (focusing on known beta-catenin target genes). DLD1, SW480, and LS174T cells were treated with siRNA or shRNA targeting beta-catenin. Microarray data was re-analyzed focusing our analysis only on the list of these 66 previously published beta-catenin target genes. Using the Biovenn software, genes that are regulated similarly in two or three cell lines were identified and listed under separate tabs. Accordingly, genes that are differentially expressed in only one cell line were listed in a separate tab labeled with the name of the cell line.

**Additional file 3:** Table S3. Results of the DNA microarray analysis (focusing on genes encoding EHLH proteins). DLD1, SW480, and LS174T cells were treated with siRNA or shRNA targeting beta-catenin. Microarray data was re-analyzed focusing our analysis only on the 96 EHLH proteins listed in the Pfam database. Using the Biovenn software, genes that are regulated similarly in two or three cell lines were identified and listed under separate tabs. Accordingly, genes that are differentially expressed in only one cell line were listed in a separate tab labeled with the name of the cell line.

**Additional file 4:** GSEA analysis using the Biocarta pathway database. This zipped file contains confirming data of the GSEA analysis. The names of the directories containing the files were composed of the term 'GSEA', the name of the cell line, e.g. DLD1, SW480, or LS174T, and the pathway database (Biocarta). Please use a web browser to view the files with the name 'index.html' in the corresponding directories to start exploring the data.

**Additional file 5:** GSEA analysis using the KEGG pathway database. This zipped file contains confirming data of the GSEA analysis. The names of the directories containing the files were composed of the term 'GSEA', the name of the cell line, e.g. DLD1, SW480, or LS174T, and the pathway database (KEGG). Please use a web browser to view the files with the name 'index.html' in the corresponding directories to start exploring the data.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
AH analyzed the data, generated the figures and drafted the manuscript. VJ performed the statistical analysis. ST and SK performed the DNA microarray experiment. HB, BG and FTK participated in the design and coordination of the study. All authors read and approved the final manuscript.

Acknowledgements
This project was supported by the grant KO1826S to F.T.K. by the German Research Council (DFG).

Author details
1Department of Medicine II, University of Munich, Marchioninistrasse 15, 81377 Munich, Germany. 2Institute for Medical Informatics, Biometry and Epidemiology, 81377 Munich, Germany. 3Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, University of Munich, 81377 Munich, Germany.

Received: 28 March 2013 Accepted: 17 January 2014 Published: 28 January 2014

References
1. Barker N, Clevers H: Mining the Wnt pathway for cancer therapeutics. Nat rev Drug discov 2006, 5:997–1014.

2. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R: Alleloype of colorectal carcinomas. Science 1989, 244:207–211.

3. Powell SM, Zlit N, Beazer-Barclay Y, Bryan TM, Hamilton SR, Thibodeau SN, Vogelstein B, Kinzler KW: APC mutations occur early during colorectal tumorigenesis. Nature 1992, 359:235–237.

4. He TC, Spirito A, Rago C, Henecke H, Zavek L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW: Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509–1512.

5. Tsetu O, McCormick F: Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 1999, 398:422–426.

6. Shuttman M, Zhirinsky J, Simcha L, Albaneese C, D’Amico M, Pestell R, Ben-Ze’ev A: The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA 1999, 96:5522–5527.

7. He TC, Chan TA, Vogelstein B, Kinzler KW: PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99:335–345.

8. Jubb AM, Chalasani S, Frantz GD, Smits R, Grabsch HI, Kavi V, Maughan NJ, Hillan KJ, Quirke P, Koeppen H: Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia. Oncogene 2006, 25:3445–3467.

9. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, Hirohashi S: Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. Cancer Res 2000, 60:4761–4766.

10. Kim PJ, Plescia J, Clevers H, Fearon ER, Ahniet DC: Survivin and molecular pathogenesis of colorectal cancer. Lancet 2003, 362:205–209.

11. Rockman SP, Currie SA, Ciavarella M, Vincan E, Dow C, Thomas RJ, Phillips WA: Id2 is a target of the beta-catenin/T-cell factor pathway in colon carcinoma. J Biol Chem 2001, 276:45113–45119.

12. Willett J, Epping M, Pollack JR, Brown PO, Nusse R: A transcriptional response to Wnt protein in human embryonic carcinoma cells. BMC Dev Biol 2002, 2:8.

13. Fujita M, Futukawa Y, Tsuorida T, Tanaka T, Oshawa M, Nakamura Y: Up-regulation of the ectodermal-neural cortex 1 (ENC1) gene, a downstream target of the beta-catenin/T-cell factor pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Res 2001, 61:7722–7726.

14. Crawford HC, Fingleton BM, Rudolph-Owen LA, Goss KJ, Polakis P, Matrisian LM: The metalloproteinase matrilysin is a target of beta-catenin transactivation in intestinal tumors. Oncogene 1999, 18:2883–2891.

15. Brabletz T, Jung A, Daeg S, Hubek F, Kirchner T: Beta-catenin regulates the expression of the matrix metalloproteinase-7 in human colorectal cancer. Am J Pathol 1999, 155:1033–1038.

16. Hubek F, Spaderna S, Jung A, Kirchner T, Brabletz T: Beta-catenin activates a coordinated expression of the proinvasive factors laminin-5 gamma2 chain and MT1-MMP in colorectal carcinomas. Int J Cancer 2004, 108:321–326.

17. Zhang X, Gaspard JP, Chung DC: Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colon neoplasia. Cancer Res 2001, 61:6050–6054.

18. Cisse B, Caton ML, Lehner M, Maeda T, Scheu S, Lockley R, Holmberg D, Zweier C, den Hollander NS, Kant SG, Holter W, Rauch A, Zhuang Y, Reisz B: Transcription factor EZ-2 is an essential and specific regulator of plasmacytoid dendritic cell development. Cell 2008, 135:37–48.

19. Leon CC, Romero MS, Ross S, Polakis P, Gao W-Q, Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells. Cancer Res 2004, 64:6050–6057.

20. Koligs FT, Nieman MT, Winer J, Hu G, Van Mater D, Feng Y, Smith IM, Wu R, Zhai Y, Cho KR, Fearon ER: ITF-2, a downstream target of the Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic transformation. Cancer Cell 2002, 1:145–153.

21. Massari ME, Murre C: Helix-loop-helix proteins: regulators of transcription in eucaryotic organisms. Mol Cell Biol 2000, 20:429–440.

22. Langklands K, Yin X, Anand G, Prochownik EV: Differential interactions of Id proteins with basic-helix-loop-helix transcription factors. J Biol Chem 1997, 272:19785–19793.

23. Heinen CD, Richardson D, White R, Groden J: Microsatellite instability in colorectal adenocarcinoma cell lines that have full-length adenomatous polyposis coli protein. Cancer Res 1995, 55:4797–4807.

24. Ilyas M, Tomlinson IP, Rowan A, Pignatelli M, Bodmer WF: Beta-catenin mutations in cell lines established from human colorectal cancers. Proc Natl Acad Sci USA 1997, 94:10330–10334.

25. Gavert N, Sheffer M, Raveh S, Spaderna S, Shuttman M, Brabletz T, Barany F, Paty P, Notterman D, Domany E, Ben-Ze’ve A: Expression of L1-CAM and
Beta-catenin and TCF mediate cell position in the intestinal epithelium by controlling the expression of EphB/ephrinB cells. Cell 2002, 111:251–263.

Shimokawa T, Furukawa Y, Sakai M, Li M, Miwa N, Lin Y-M, Nakamura Y: Involvement of the FGF18 gene in colorectal carcinogenesis, as a novel downstream target of the beta-catenin-T cell--factor complex. Cancer Res 2003, 63:6116–6122.

Ray R, Cabe-Manzano R, Moser AR, Waldman T, Zipper LM, Agirn A, Byers SW, Regel AT, Weltstein A: Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon cancer. Cancer Res 2003, 63:8085–8089.

Mann B, Gelos M, Siedow A, Hanski ML, Gratchev A, Ayas M, Bormod WF, Moyer MP, Recken EO, Buhr HJ, Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999, 96:1563–1568.

Vigneved C, Schoumacher M, Gavert N, Janssen K-P, Jih G, Læl M, Louvard D, Ben-Zeév A, Robine S, Faschin A, a novel target of beta-catenin-TCF signaling, is expressed at the invasive front of human colon cancer. Cancer Res 2007, 67:6844–6855.

Li H, Li Y, Van Sorten B, Fornaciari G, Koeberle J, Schimmelpfennig S, Hafner B, Jansen F, Moeschler J: Gastrin is a target of the beta-catenin/TCF-4 growth-signaling pathway in a model of intestinal polypysis. J Clin Invest 2000, 106:533–539.

Lapham A, Adams JE, Paterson A, Lee M, Brimmell M, Packham G: Identification of CDX2 as a bona fide morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002, 62:2744–2748.

Wetling SJ, Murr S, Korinke M, Smit L, Kielman M, Fodde R, Clevers H: Expression of CD44 in Apc(Min/+). Nature Genet 2009, 41:112–117.

Yu T, Chen X, Zhang W, Colon D, Shi J, Napier D, Rychahou P, Lu W, Lee EY, Weiss HL, Evers BM, Liu C: Regulation of human nitric oxide synthase 2 expression by beta-catenin/TCF-4 in colon cancer cells. Mol Cell Biol 2002, 22:1712–1735.

Kim J-S, Crooks H, Dracheva T, Nishimura T, Singh S, Chen J, Jen J, Waldman T: Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. Cancer Res 2002, 62:2744–2748.

Akiyama T: Involvement of the WNT target and cancer stem cell marker CD44 in Apc(Min/+). Cancer Res 2001, 61:8085–8093.

Vaneckova E, Villarreal B, Ben-Shitrit L, Enyeart JD, Daller C, Janssen K-J, Clevers H: Expression of the invasion factor laminin gamma 2 in colorectal cancer is regulated by beta-catenin. Cancer Res 2001, 61:10289–10293.

Hovanes K, Li TW, Ting J-H, Yokoyama NN, Bernstein A, van den Eertwegh M, Waterman JM: Regulation of human nitric oxide synthase 2 expression by the Wnt pathway. Life Sci 2005, 77:1249–1256.

Delhaye M, van den Berghe P, Nuyens D, Vukicevic M, Vaneckova E, Clevers H: Positive cross-talk between beta-catenin and notch effects in intestinal tumorigenesis. Gut 2011, 60:166–176.

Rodilla V, Villanueva A, Obrador-Hevia A, Robert-Moreno A, Fernández-Majada V, Grilli A, López-Bigas N, Bellora N, Albá MM, Torres F, Duñach M, Sanjuán X, González S, Grindley T, Capella G, Bigas A, Espinosa L: LMO7 is a downstream target of Wnt in breast cancer. Breast Cancer Res 2009, 11:R66.

Batlle E, Henderson JT, Begthel H, van den Born MMW, Sancho E, Huls G, Moerker M, van der Horn K, Batlle E, Coudreuse D, Haramis AP, Tjon-Pon-Fong M, Moyer MP, Recken EO, Buhr HJ, Hanski C: Target genes of beta-catenin-T cell-factor/lymphoid-enhancer-factor signaling in human colorectal carcinomas. Proc Natl Acad Sci USA 1999, 96:1563–1568.

Baehs S, Herbst A, Thieme SE, Perschl C, Behrens A, Scheel S, Jung A, Mörnes K, Elander N, Grünberg J, Sigvardsson M, Söderkvist P, The beta-catenin/T cell-factor complex induces expression of EphB/ephrinB2 in colorectal cancer cells. Mol Cell Biol 2002, 22:1712–1735.

Wieting M, Clevers H, Schip PM, Brincker N, Wehrens J: Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002, 22:1184–1193.

Baehs S, Herbst A, Thieme SE, Perschl C, Behrens A, Scheel S, Jung A, Mörnes K, Elander N, Grünberg J, Sigvardsson M, Söderkvist P, The beta-catenin/T cell-factor complex induces expression of EphB/ephrinB2 in colorectal cancer cells. Mol Cell Biol 2002, 22:1712–1735.

Wieting M, Clevers H, Schip PM, Brincker N, Wehrens J: Negative feedback loop of Wnt signaling through upregulation of conductin/axin2 in colorectal and liver tumors. Mol Cell Biol 2002, 22:1184–1193.

Herbst et al. BMC Genomics 2014, 15:74 http://www.biomedcentral.com/1471-2164/15/74 Page 13 of 15
66. Conacci-Sorrell ME, Ben-Yedidia T, Shutman M, Feinstein E, Einat P, Ben-Ze'ev A: NC-CAM is a target gene of the beta-catenin/LEF-1 pathway in melanoma and colon cancer and its expression enhances motility and confers tumorigenesis. *Genes Dev* 2002, 16:2058–2072.

67. Hendrikmeyer E, Regus S, Wassermann S, Hubek F, Hayril A, Dimmler A, Koch K, Knoll C, van Berlo M, Reuning U, Brabitz T, Kirchner T, Jung A: Beta-catenin regulates the expression of the urokinase plasminogen activator in human colorectal cancer. *Cancer Res* 2004, 64:1209–1214.

68. Stein U, Aff T, Walther S, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birringer W, Schlag PM, Shoemaker RH: The metastasis-associated gene S10A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. *Gastroenterology* 2006, 131:1486–1500.

69. Klařicžek E, Graczyk A, Ostrowiska H, Kasacka J, Lestniček W, Filipiak A: S10A4 is transcriptionally regulated by β-catenin and interacts with a novel target, lamin A/C, in colorectal cancer cells. *Cell Calcium* 2012, 51:470–477.

70. Dehmer M, Hadijannas M, Weiske J, Huber O, Behrens J: Beta-catenin signaling inhibits Forkhead box O3a-induced transcription and apoptosis through up-regulation of serum- and glucocorticoid-inducible kinase 1. *J Biol Chem* 2006, 281:19211–19210.

71. Ghiselli G, Coffee N, Munnery CE, Koratkar R, Siracusa LD: The cohesin SMCD3 is a target for the beta-catenin/TCF4 transactivation pathway. *J Biol Chem* 2003, 278:20259–20267.

72. Blache P, van de Wetering M, Duluc J, Dornon C, Berta P, Freund J-H, Clevers H, Jay P: SOX9 is an intestine crypt transcription factor, is regulated by the Wnt pathway, and represses the CDX2 and MUC2 genes. *J Cell Biol* 2004, 166:47–57.

73. Takahashi M, Nakamura Y, Obama K, Furukawa Y: Identification of SPS as a downstream gene of the beta-catenin/Tcf pathway and its enhanced expression in human colon cancer. *Int J Oncol* 2005, 27:1483–1487.

74. Gonçalves V, Mato S, Jordan P: The beta-catenin/TCF4/TCF pathway modifies alternative splicing through modulation of SRp20 expression. *RNA* 2008, 14:2539–2546.

75. Kirmizis A, Bartley SM, Fanham PJ: Identification of the polycystin group protein SUZ12 as a potential molecular target for human cancer therapy. *Mol Cancer Ther* 2003, 2:113–121.

76. Roose J, Huls G, van Beest M, Moerer P, van der Horn K, Goldschmeding R, Logtenberg T, Clevers H: Synergy between tumor suppressor APC and the beta-catenin-Tcf4 target Tcf1. *Science* 1999, 285:1923–1926.

77. Malliri A, Rygiel TP, van der Kammen RA, Song J-Y, Engers R, Hurlstone AFL, Herbst et al: BMC Genomics 2003, 68: Stein U, Arlt F, Walther W, Smith J, Waldman T, Harris ED, Mertins SD, Heizmann CW, Allard D, Birringer W, Schlag PM, Shoemaker RH: The metastasis-associated gene S10A4 is a novel target of beta-catenin/T-cell factor signaling in colon cancer. *Gastroenterology* 2006, 131:1486–1500.

78. Logtenberg T, Clevers H: Beta-catenin signaling regulates Yes-associated protein (YAP) gene expression in colorectal cancer cells. *J Biol Chem* 2005, 280:19201–19210.

79. Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP: The APC tumour suppressor controls beta-catenin function in transcription. *EMBO J* 2003, 22:1101–1113.

80. Rosin-Arbeil R, Cliffe A, Brabitz T, Biezen M: Nuclear export of the APC tumour suppressor controls beta-catenin function in transcription. *EMBO J* 2003, 22:1101–1113.

81. Persad S, Trousdale AA, McPhee TR, Mulhalland DJ, Dedhar S: Tumor suppressor PTEN inhibits nuclear accumulation of beta-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. *J Cell Biol* 2001, 153:161–174.

82. Deming DA, Leystra AA, Nettekoven L, Sievers C, Miller D, Middlebrook M, Clipsom L, Albrecht D, Sacher J, Washington MK, Weichert J, Halberg R: PIK3CA and APOC mutations are synergistic in the development of intestinal cancers. Oncogene 2013. doi:10.1038/onc.2013.167.

83. Liu J, Stevens J, Rote CA, Yost H, Hu Y, Neufeld KL, White RL, Matsunami N: Siah-1 mediates a novel beta-catenin degradation pathway linking p53 to the adenomatous polyposis coli protein. *Mol Cell* 2001, 7:927–936.

84. Matsuoka S, Reed JC. Siah-1, SIP, and Ebi collaborate in a novel pathway for beta-catenin degradation linked to p53 responses. *Mol Cell* 2001, 7:915–926.

85. Rother K, Johne C, Spiebsch K, Haugwitz U, Tschöp K, Wasner M, Hiolin L, Petzold T, Koch W, Möray T, Mössner J, Engeland K: Identification of Tcf-4 as a transcriptional target of p53 signalling. *Oncogene* 2004, 23:3376–3384.

86. Nak M, Kim KS, Kim N-G, Lee I, Choi H-S, Li X-Y, Kang SE, Cha SY, Ryu JK, Na JM, Park C, Kim K, Lee S, Gumbiner BM, Yook J, Weiss SD: p53 and microRNA-34 are suppressors of canonical Wnt signalling. *Science Signal* 2011, 44:ra71.
109. Crampton SP, Wu B, Park EI, Kim JH, Solomon C, Waterman ML, Hughes CCW: Integration of the beta-catenin-dependent Wnt pathway with integrin signaling through the adaptor molecule Grb2. PLoS ONE 2009, 4:e7841.

110. Yang Y: Wnt signaling in development and disease. Cell Biosci 2012, 2:14.

111. Benetti R, Copetti T, Dell’Orso S, Melloni E, Brancolini C, Monte M, Schneider C: The calpain system is involved in the constitutive regulation of beta-catenin signaling functions. J Biol Chem 2005, 280:22070–22080.

112. Li G, Iyengar R: Wnt signaling in development and disease. Cell Biosci 2012, 2:14.

113. Pradeep A, Sharma C, Sathyanarayana P, Albanese C, Fleming JV, Wang TC, Wolfe MM, Baker KM, Pestell RG, Rana B: Gastrin-mediated activation of cyclin D1 transcription involves beta-catenin and CREB pathways in gastric cancer cells. Oncogene 2004, 23:3689–3699.

114. Yang Y: Wnt signaling in development and disease. Cell Biosci 2012, 2:14.

115. Hu Q, Lee SY, O'Kusky JR, Ye P: Signaling Through the Type 1 Insulin-Like Growth Factor Receptor (IGF1R) Interacts with Canonical Wnt Signaling to Promote Neural Proliferation in Developing Brain. ASN Neuro 2012, 4:253–265.

116. Tanaka A, Itoh F, Nishiyama K, Takezawa T, Kurihara H, Itoh S, Kato M: Inhibition of endothelial cell activation by bHLH protein E2-2 and its impairment of angiogenesis. Blood 2010, 115:4138–4147.

117. Van der Flier LG, Van Gijn ME, Hatzis P, Kujala P, Haegebarth A, Stange DE, Begthel H, van den Born M, Guryev V, Oving I, van Es JH, Barker N, Peters PJ, van de Wetering M, Clevers H: Transcription factor achaete scute-like 2 controls intestinal stem cell fate. Cell 2009, 136:903–912.

118. Hulsen T, de Vlieg J, Akkermans W: BioVenn - a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams. BMC Genomics 2008, 9:488.

119. Smoot ME, Ono K, Ruscheinski J, Wang P-L, Ideker T: Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 2011, 27:431–432.

120. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Research 2002, 30:207–210.